Supriya Lifescience Ltd. Stock Analysis SUPRIYA.NS

Supriya Lifescience Ltd. supplies active pharmaceuticals ingredients (“APIs”), with a focus on research and development. The company is headquartered in Mumbai, Maharashtra and currently employs 515 full-time employees. The company went IPO on 2021-12-28. The firm is primarily engaged in the manufacturing of bulk drugs and pharmaceutical chemicals. The firm exports its products in the antihistamine, anesthetics and anti-asthma therapy categories to approximately 86 countries. The firm's product portfolio consists of approximately 38 API products that offer remedies in therapeutic segments, such as antihistamines, analgesics, vitamins, anesthetics and anti-asthmatics, among others. Its products include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulfate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride, among others. The firm has manufacturing facilities located in Maharashtra.